{"name":"Pyramid Biosciences","slug":"pyramid-biosciences","ticker":"","exchange":"","domain":"","description":"Pyramid Biosciences is a biopharmaceutical company focused on developing innovative treatments across various therapeutic areas. The company has a pipeline of six drugs, with several in early-stage clinical trials, aiming to address significant unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9uSDlYWEpJYXdhQ2drQzhYOHJLd0twQ2Y1WE9rdGlISEk2ZngwWG9ETDNGMHpKQ2Utb0tVcGFNTGVvdEt6VjN1aWE0YWlMaThtd3l2TVdYQ3Z0cEw1RDJFZHlkZnU2WEZUMTdJdGd3ZHFzNUk?oc=5","date":"2025-10-15","type":"trial","source":"Taylor & Francis Online","summary":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: Future Oncology: Vol 21, No 25 - Taylor & Francis Online","headline":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPeGU2S1JUNjBZRVd5QXo1Q1ZqWjVoRjdpMkQwRVh4bkhsZG5fTXRSZnpaWUZ4TWlwRHNHQ1lLb2FVWEZlR2o3Z3pBZkk1Y0RWRVctYVlld18zUEVOXzlRYmR6MXIzcW5lcEd2MlBKR1lwVHZVZEZyai1VQ0VULUF2S3QzamtsTjU2ZWkyczU2clJTRlVSeVlRa1lPakhFemJSNEhyb0FkTjVZSjN3YWlPSk5NQVkzRlFXenUyRDZEZElTTkVHd1ptc01KdlJVd1ROdjhVVktScktQdw?oc=5","date":"2025-05-12","type":"earnings","source":"PR Newswire","summary":"Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments - PR Newswire","headline":"Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPc2FSc0ZEdElOeVNwa2VYb2FyN2l3RDNGbG8zWkRrbUJfUlNLRnpZVFVaLWJrdFQ2T09abERLeVNfVjJQcWpZRnJ1QXBSMlhSdF9nOXIyMFNjb2ZYQW45LWd0dTlDVE93NDJzVTRRVGtyRFA5QVlBN194SnMzUUN6QVlzS0NxRWxGWnA1aTBR?oc=5","date":"2024-12-06","type":"trial","source":"Oncology Pipeline","summary":"Biohaven aims to become an oncology fast follower | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Biohaven aims to become an oncology fast follower | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOLTZtcnhNX0E3bEM4N1N2bWkxQzdaejU2MmUzTHhYRDJZd2RCR3JLSmJlSktZRWRRaWZscEtSR3J4ZFBfXzNIQmNmLUdZbGJQbldTVjBSRjBTbVpJU1JWTEcybVBvclZsNHpSOWRSMW5MMVpDQUwyRG1hdm1fbk9JejB4OS1XUnpZYkRxbFBxUFUyVnN1OU02SDVWbGxFS25oMHRzQkdDZmNMQ2RCVy1rZTNlYVZBYWc?oc=5","date":"2024-10-04","type":"trial","source":"Endpoints News","summary":"After $14B exit, Karuna co-founder finds next bet; Ex-Regenxbio CEO Ken Mills heads to Tagworks - Endpoints News","headline":"After $14B exit, Karuna co-founder finds next bet; Ex-Regenxbio CEO Ken Mills heads to Tagworks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNR1hpT2gxamNHTVIwMWY2WEtWV1dMUzIxSWotb2FFak5yUHpaWVZHXzBpVFVJbkd5elpMWE9jWWxNUW4yVnBZLWg0WWFoMUk1S3dBVFFfMFJwMHZ3TGJsbUl1TVZMOHpzT01GRTQ2QmpxZExqQnVJeUJQYUp0U1pGM3d1N29vaTF4OHIxR2d3?oc=5","date":"2024-03-22","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech","headline":"Chutes & Ladders—Bayer undergoes leadership shake-up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPT2gzaDJKSWJhQUI2UW9ITmtmU2kxTUwyQUNmMlJqYzdqWHVBcS13cm5vZ3BQazlMQm9CczhUVGdCTm83ZkJCZDBhcXg3RTJqN3J3WUk4YlZuQ19lMEhGbkxXZHpEdmVwVmtCNWQyNmNxUmNSR05PWGlqNk1ScjJwb1JJSXN1UEpSMWFvdHln?oc=5","date":"2024-03-06","type":"pipeline","source":"Contract Pharma","summary":"Pyramid Labs Appoints Dirk Lange as CEO - Contract Pharma","headline":"Pyramid Labs Appoints Dirk Lange as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPSXBEQm1JRVZyQ293TEZ2UkpPX3o0T1RHX3U0cjN6SG84UVdxTHllTVNybGxoNDNqZ28wczVEYlFvUEFVQTRwOW93dGZYMlM4dXNWbVJ3SHkxUERiblFEWDB1ZnVhMnh6Zjg2ZFlRRkQtVVFFMmVrdnNpaTh3Qjg3YndfdDlCZE81VkdsR25UVmNmSnBRZl9CbQ?oc=5","date":"2024-01-19","type":"deal","source":"Pharmaceutical Executive","summary":"Out-licensing Deals Between Chinese Pharma and Global Companies are Heating Up - Pharmaceutical Executive","headline":"Out-licensing Deals Between Chinese Pharma and Global Companies are Heating Up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNS3ZXLU1BcDhKUWdldUdIczRyY04yVzBVY2xDUEprMmREWGJWSGZodDNRRkFkZVVWZVcxdEEwTzdhSWdOVzJDeVU0anNpcEVLSjFwa09UYkhwdkJMQXBxQkZ2ZXhVNlRoMHBZQ0xyYVNfWWp4eHFGVDBGMmJmdXNZTUx2bGNFOEtma0FHUkFXRWVpZ18xTldsQzdrR2E?oc=5","date":"2023-09-12","type":"pipeline","source":"Contract Pharma","summary":"Pyramid Names Industry Veterans to Leadership Posts - Contract Pharma","headline":"Pyramid Names Industry Veterans to Leadership Posts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNcjRVa2tfWVBQdHVMTWRhV1pnZjY3ZGZjNnlwNjJBZmZnVnVQYS1vb0szczBoOFZsWk5lcDNDR09HM2h1dTdyMU96UTNHN2dCOU5WQXNQYVBCTzIteU5jcEtGMFBaUjROMmYyNjdJUXlwdDNfTmpZaHZ3eWtBVVN3QmgxME10TDNHZGM3TUpHeVF4Q19mdDRHUlVYcnE?oc=5","date":"2023-04-18","type":"pipeline","source":"Contract Pharma","summary":"Audax Private Equity Invests in Pyramid Laboratories - Contract Pharma","headline":"Audax Private Equity Invests in Pyramid Laboratories","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1MLVFBOUJ3aGE0eUc2cXg2YlN0NkpUQ0ROTlB2cFBUX0VFcDVRQ092MTZ2anRFNzZzTFFOQlYyMnVYdDlraFA4d2xXUlhTd09LUjdTdkoweXRfNS1sV2t2U2hkYUZEYzJsV0dScW5fd0Vidw?oc=5","date":"2022-03-04","type":"pipeline","source":"KED Global","summary":"Korea’s Voronoi in talks with global firms on drug designs - KED Global","headline":"Korea’s Voronoi in talks with global firms on drug designs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE5YUTE5UVJzRUxzTThYQVRtVXZQdHNoQUpOaVFvaGdGTFlGVGE0V3pha0FJek1YbzEzVUE3UEZyS3k2dEVmOG9uMXhfME5sTzBTM2RTeDRfVFpORjhsQmloVHBVbFE?oc=5","date":"2021-11-18","type":"pipeline","source":"KED Global","summary":"K-bio's out-licensing this year reaches $9.3 bn - KED Global","headline":"K-bio's out-licensing this year reaches $9.3 bn","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}